Li Jingyang increased his holding of Huakang Biomed (08622) by approximately 139 million shares, with a price of 0.1175 Hong Kong dollars per share.

19:59 16/01/2025

On January 10th, Li Jingyang increased his holdings of Huakang Biomedical (08622) by 138.672 million shares, with a price of 0.1175 Hong Kong dollars per share, for a total amount of 16.29396 million Hong Kong dollars.

According to the latest information from the Hong Kong Stock Exchange, on January 10th, Li Jingyang increased his holdings of Huakang Biomedical (08622) by 138.672 million shares, at a price of HK$0.1175 per share, for a total amount of HK$16.29396 million. After the increase, the latest number of shares held is 138.672 million, with a latest shareholding percentage of 27.71%.

BRONCUS-B(02216) plans to further acquire 3.85% equity of Valgen Holding Corporation for 55.12 million US dollars.

XUANZHUBIO-B(02575): Omeprazole enteric-coated tablets (Anjiuwei) completed the enrollment of all subjects in the Phase III clinical trial for the treatment of reflux esophagitis in China.

CA CULTURAL (01566) releases annual performance, with a shareholder's loss of HK$33.043 million, a year-on-year decrease of 80.64%.

BRONCUS-B(02216) plans to further acquire 3.85% equity of Valgen Holding Corporation for 55.12 million US dollars.

XUANZHUBIO-B(02575): Omeprazole enteric-coated tablets (Anjiuwei) completed the enrollment of all subjects in the Phase III clinical trial for the treatment of reflux esophagitis in China.

CA CULTURAL (01566) releases annual performance, with a shareholder's loss of HK$33.043 million, a year-on-year decrease of 80.64%.